MicroPort CardioFlow Medtech Corporation · HKEX:2160

MicroPort CardioFlow Medtech — H1 2022 Earnings Presentation

27 slides from MicroPort CardioFlow Medtech's earnings presentation, September 2022

  1. Slide 1: 2022 Interim Results Presentation

    (2160.HK) MicroPort CardioFlow Medtech Corporation 2022 Interim Results Presentation September 2022

  2. Slide 2: Disclaimer

    Disclaimer MicroPort CardioFlow Medtech Corporation This presentation was prepared by MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司) (the “Company”) solely for use at the presentation held in September 2022. The information contained in this presentation has not been reviewed by any regulat

  3. Slide 3: Agenda

    MicroPort CardioFlow Medtech Corporation Agenda Company Product Pipeline Appendix Highlights Update 03 11 21 Business Financial Review Review 06 18 02

  4. Slide 4: Company Highlights

    Company Highlights 03

  5. Slide 5: Delivering Rapid Growth Amidst COVID Headwinds

    Delivering Rapid Growth Amidst COVID Headwinds A Glance of 1H22 Our Achievements Revenue +45% with increasing contribution by VitaFlow LibertyTM and expanding overseas business Revenue Implantation volume* Implantation +60% with continued record-breaking weekly and RMB 125 mn 44.8%YOY 1,335 60%YOY m

  6. Slide 6: Strong Topline Growth with Steadily Improving Margin

    Strong Topline Growth with Steadily Improving Margin Revenue Gross Profit and GPM Cash and Cash Equivalents (RMB'000) (RMB'000) (RMB'000) Including term deposits 2,403,587 11.0 pts % 8.6p 63.7% + 2,139,064 55.1% 124,782 8% 79,443 44. .2% 86,193 67 47,511 1H21 1H22 1H21 1H22 End of 2021 End of 1H22 I

  7. Slide 7: Business Review

    Business Review 06

  8. Slide 8: Market-beating Growth Propelled by Product Excellence

    Market-beating Growth Propelled by Product Excellence Revenue (RMB mn) Hospital Coverage 1H22 Commercialization Progress China End of 2021 Overseas 124.8 End of 1H22 1,335 procedures performed with our TAVI family products, 8% 44. 1.8 fast penetrating the domestic market 86.2 Record high weekly and

  9. Slide 9: Targeted Total Solutions Promotion for Patients and Physicians

    Targeted Total Solutions Promotion for Patients and Physicians Academic Conference Participation Patient Needs-centric Approach Attended 43 domestic academic conferences including OCC and China Enhanced discovery and referral schemes, Valve, hosted 154 seminars and initiated 23 training activities w

  10. Slide 10: Leveraging the Mature Channels and Brand Influence of MicroPort in Overseas Expansion

    Leveraging the Mature Channels and Brand Influence of MicroPort® in Overseas Expansion CE Overseas expansion led by our core TAVI Products VitaFlow LibertyTM : continued progress under MDR regulations 3 products entered the overseas market, 5 certificates Alwide® Plus: summitted registration applica

  11. Slide 11: Strengthened Lean Manufacturing and Improved Cost Structure

    Strengthened Lean Manufacturing and Improved Cost Structure Lean manufacturing deployment On-time production and including Flow Meeting, Gemba delivery against sporadic COVID Walk, Suggestion System for breakouts ensuring the smooth operational excellence in quality, running of business people, cust

  12. Slide 12: Product Pipeline Update

    Product Pipeline Update >) MicroPort™ its 36 EB iF lit

  13. Slide 13: Innovative and High-quality Total Solutions for Structural Heart Diseases

    Innovative and High-quality Total Solutions for Structural Heart Diseases TAVI TMV 2 launched, 3 under R&D 5 pipeline products: 3 TMVR and 2 TMVr Increasing domestic market share and Inhouse R&D + Collaboration with global e Mi continued overseas implantation valv tra l va partners Valcare and 4C Me

  14. Slide 14: Our TAVI Family: Positive Clinical Trial Results and KOL Endorsements

    Our TAVI Family: Positive Clinical Trial Results and KOL Endorsements VitaFlow® VitaFlow LibertyTM Valve Transcatheter Aortic Valve Implantation System Valve Transcatheter Aortic Valve Implantation System Relatively lower all-cause mortality rate Significantly reduced intraoperative valve-in-valve i

  15. Slide 15: Inhouse Developed TAVI Pipeline Products with Innovative Upgrades

    Inhouse Developed TAVI Pipeline Products with Innovative Upgrades Category Product Features Progress VitaFlow®III Reduced profile for improved vascular Design spoken highly of by KOLs Self-Expanding complications Chronic animal studies in preparation Catheter articulation for improved delivery and A

  16. Slide 16: Complete MR Toolbox Covering All Mainstream Viable TVT Options

    Complete MR Toolbox Covering All Mainstream Viable TVT Options Category Product Features Progress TMVr product Differentiated deployment for ease of use Design fixing (In-house development) Unique lock mechanism for stable leaflet capture Low profile TMVr* AMEND Innovative ring design with unique an

  17. Slide 17: Designing and Proving Disruptive TTV and Surgical Valve Products

    Designing and Proving Disruptive TTV and Surgical Valve Products Category Product Features Progress Edge to Edge Differentiated deployment for ease of use Design stage (In-house development) Unique lock mechanism for stable leaflet capture Low profile TTVr* TRIVID Unique anchoring capabilities Anima

  18. Slide 18: A Comprehensive Portfolio of Self-developed TAVI Procedural Accessories

    A Comprehensive Portfolio of Self-developed TAVI Procedural Accessories Category Product Features Progress Alwide® balloon More Stable position during Submitted for NMPA Approval catheter III inflation High burst pressure suits for severe calcification conditions Procedural Expandable sheath Reducin

  19. Slide 19: Financial Review

    Financial Review >) MicroPort™ its 36 EB iF 18

  20. Slide 20: Rapid Revenue Growth Coupled by Increase in Gross Profit

    Rapid Revenue Growth Coupled by Increase in Gross Profit Revenue (RMB’000) Gross Profit (RMB'000) Gross Profit Margin (%) 124,782 4.8 % p pts 63.7% 4 .6 +8 86,193 79,443 % 7 .2 6 55.1% 47,511 1H21 1H22 1H21 1H22 1H21 1H21 Our revenue increased by 45% in 1H22 mainly from the increase on sales volume

  21. Slide 21: Continued Investment in R&D, Commercialization and Production Capacity

    Continued Investment in R&D, Commercialization and Production Capacity We focused on strengthening our R&D pipelines, keeping our commercialization competitiveness and expanding our production capacity for future growth, with increased operational expenses increased on track. R&D Expenses (RMB'000)

  22. Slide 22: Appendix

    Appendix 21

  23. Slide 23: Appendix 1: Overview of Product Pipeline

    Appendix 1: Overview of Product Pipeline Product Pre-clinical Clinical trial Registration Launched VitaFlow® Successfully registered in Argentina and Thailand VitaFlow® System Launched Alwide® balloon catheter* Successfully registered in Argentina and Thailand Launched VitaFlow LibertyTM (Retrievabl

  24. Slide 24: Appendix 2: TAVI Products - Clinical Data Comparison

    Appendix 2: TAVI Products - Clinical Data Comparison 30-days 1-year 1-year 2-year 3-year 4-year 5-year 30-days major 1-year major moderate to 1-year major 2-year major 3-year major 4-year major 5-year major mortality (disabling) mortality (disabling) severe PVL vascular mortality (disabling) mortali

  25. Slide 25: Consolidated Income Statement

    Consolidated Income Statement Unit: RMB'000 2022 1H 2021 1H Var. Revenue 124,782 86,193 45% Cost of sales (45,339) (38,682) 17% Gross profit 79,443 47,511 67% Other net income 12,070 7,711 57% Research and development costs (79,610) (48,998) 62% Distribution costs (61,048) (39,475) 55% Administrativ

  26. Slide 26: Consolidated Balance Sheet

    Consolidated Balance Sheet June 30, 2022 December 31, 2021 Unit: RMB'000 Var. (Unaudited) (Audited) Non-current assets Property, plant and equipment 260,102 267,166 -3% Intangible assets 225,800 238,752 -5% Interest in a joint venture 34,865 33,219 5% Interests in associates 293,310 176,738 66% Othe

  27. Slide 27: Our Mission

    Our Mission To provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases

MicroPort CardioFlow Medtech — H1 2022 Earnings Presentation on 6ix